Algert Global LLC Sells 9,810 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Algert Global LLC trimmed its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 39.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,779 shares of the company’s stock after selling 9,810 shares during the period. Algert Global LLC’s holdings in Trevi Therapeutics were worth $61,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Summit Investment Advisors Inc. increased its position in Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after purchasing an additional 2,894 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Trevi Therapeutics during the fourth quarter worth about $49,000. China Universal Asset Management Co. Ltd. acquired a new position in Trevi Therapeutics during the 4th quarter valued at approximately $67,000. Jump Financial LLC acquired a new position in shares of Trevi Therapeutics in the 4th quarter valued at $89,000. Finally, Invesco Ltd. raised its stake in shares of Trevi Therapeutics by 21.2% in the fourth quarter. Invesco Ltd. now owns 23,621 shares of the company’s stock worth $97,000 after purchasing an additional 4,133 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on TRVI shares. B. Riley restated a “buy” rating and set a $20.00 target price (up from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. D. Boral Capital reiterated a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Oppenheimer increased their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Needham & Company LLC reiterated a “buy” rating and set a $24.00 price objective on shares of Trevi Therapeutics in a research report on Tuesday, April 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.50 target price on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Trevi Therapeutics currently has a consensus rating of “Buy” and an average price target of $17.56.

Trevi Therapeutics Trading Down 3.7%

TRVI stock opened at $6.45 on Wednesday. The company has a market capitalization of $644.31 million, a PE ratio of -14.66 and a beta of 0.62. The business’s fifty day moving average price is $6.24 and its 200 day moving average price is $4.58. Trevi Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $7.39.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.04. Research analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jennifer L. Good sold 5,263 shares of the company’s stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $1,403,599.54. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Farrell Simon sold 81,313 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares in the company, valued at $519,075. This represents a 51.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.37% of the stock is owned by insiders.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.